Literature DB >> 36076011

CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era.

John L Vaughn1, Samantha Brown2, Esperanza B Papadopoulos1,3, Ann A Jakubowski1,3, Roni Tamari1,3, Sergio A Giralt1,3, Doris M Ponce1,3, Christina Cho1,3, Miguel-Angel Perales1,3, Brian C Shaffer1,3, Boglarka Gyurkocza4,5.   

Abstract

Entities:  

Year:  2022        PMID： 36076011     DOI： 10.1038/s41409-022-01783-7

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.174


× No keyword cloud information.
  6 in total

1.  Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.

Authors:  Anna Lübking; Arta Dreimane; Fredrik Sandin; Cecilia Isaksson; Berit Märkevärn; Mats Brune; Per Ljungman; Stig Lenhoff; Leif Stenke; Martin Höglund; Johan Richter; Ulla Olsson-Strömberg
Journal:  Bone Marrow Transplant       Date:  2019-04-08       Impact factor: 5.483

2.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

3.  Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.

Authors:  Aleksandar Radujkovic; Sascha Dietrich; Henric-Jan Blok; Arnon Nagler; Francis Ayuk; Jürgen Finke; Johanna Tischer; Jiri Mayer; Yener Koc; Federica Sorà; Jakob Passweg; Jenny L Byrne; Pavel Jindra; Joan Hendrik Veelken; Gerard Socié; Johan Maertens; Nicolaas Schaap; Michael Stadler; Maija Itälä-Remes; Eleni Tholouli; Mutlu Arat; Vanderson Rocha; Per Ljungman; Ibrahim Yakoub-Agha; Nicolaus Kröger; Yves Chalandon
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-01       Impact factor: 5.742

4.  Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.

Authors:  Leo Luznik; Marcelo C Pasquini; Brent Logan; Robert J Soiffer; Juan Wu; Steven M Devine; Nancy Geller; Sergio Giralt; Helen E Heslop; Mary M Horowitz; Richard J Jones; Mark R Litzow; Adam Mendizabal; Lori Muffly; Eneida R Nemecek; Lynn O'Donnell; Richard J O'Reilly; Raquel Palencia; Johannes Schetelig; Leyla Shune; Scott R Solomon; Sumithira Vasu; Vincent T Ho; Miguel-Angel Perales
Journal:  J Clin Oncol       Date:  2021-12-02       Impact factor: 44.544

5.  HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome.

Authors:  D I Marks; T P Hughes; R Szydlo; S Kelly; J O Cullis; A P Schwarer; S Mackinnon; J Apperley; A J Barrett; J M Hows
Journal:  Br J Haematol       Date:  1992-07       Impact factor: 6.998

6.  Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia.

Authors:  Ahmet H Elmaagacli; Rudolf Peceny; Nina Steckel; Rudolf Trenschel; Hellmut Ottinger; Hans Grosse-Wilde; Ulrich W Schaefer; Dietrich W Beelen
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.